Novo Nordisk A/S (NVO)
47.64
+4.30
(+9.92%)
USD |
NYSE |
Feb 06, 16:00
50.37
+2.73
(+5.73%)
Pre-Market: 07:31
Novo Nordisk SG&A Expense (TTM) : 10.66B for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Ascendis Pharma A/S | 446.44M |
| Evaxion AS | 6.00M |
| Regeneron Pharmaceuticals, Inc. | 2.70B |
| Viking Therapeutics, Inc. | 52.36M |
| DBV Technologies SA | 28.71M |